Collegium Pharmaceutical Valuation
| COLL Stock | USD 30.50 0.21 0.68% |
At this time, the firm appears to be fairly valued. Collegium Pharmaceutical shows a prevailing Real Value of $30.93 per share. The current price of the firm is $30.5. Our model approximates the value of Collegium Pharmaceutical from analyzing the firm fundamentals such as Return On Equity of 0.43, profit margin of 0.15 %, and Current Valuation of 1.74 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Collegium Pharmaceutical's valuation include:
Price Book 4.2275 | Enterprise Value 1.7 B | Enterprise Value Ebitda 5.0324 | Price Sales 1.6528 | Forward PE 4.845 |
Fairly Valued
Today
Please note that Collegium Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Collegium Pharmaceutical is based on 3 months time horizon. Increasing Collegium Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Collegium stock is determined by what a typical buyer is willing to pay for full or partial control of Collegium Pharmaceutical. Since Collegium Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Collegium Stock. However, Collegium Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 30.5 | Real 30.93 | Target 33.5 | Hype 30.24 | Naive 31.16 |
The intrinsic value of Collegium Pharmaceutical's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Collegium Pharmaceutical's stock price.
Estimating the potential upside or downside of Collegium Pharmaceutical helps investors to forecast how Collegium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Collegium Pharmaceutical more accurately as focusing exclusively on Collegium Pharmaceutical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Collegium Pharmaceutical's intrinsic value based on its ongoing forecasts of Collegium Pharmaceutical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Collegium Pharmaceutical's closest peers.
Collegium Pharmaceutical Cash |
|
Collegium Valuation Trend
Knowing Collegium Pharmaceutical's actual value is paramount for traders when making sound investment determinations. Using both Collegium Pharmaceutical's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Collegium Revenue by Product
Collegium Pharmaceutical Total Value Analysis
Collegium Pharmaceutical is currently expected to have valuation of 1.74 B with market capitalization of 990.4 M, debt of 674.28 M, and cash on hands of 122.72 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Collegium Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.74 B | 990.4 M | 674.28 M | 122.72 M |
Collegium Pharmaceutical Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The book value of Collegium Pharmaceutical was currently reported as 7.27. The company had not issued any dividends in recent years. Based on the analysis of Collegium Pharmaceutical's profitability, liquidity, and operating efficiency, Collegium Pharmaceutical is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in December.Collegium Pharmaceutical Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Collegium Pharmaceutical has an asset utilization ratio of 49.57 percent. This suggests that the Company is making $0.5 for each dollar of assets. An increasing asset utilization means that Collegium Pharmaceutical is more efficient with each dollar of assets it utilizes for everyday operations.Collegium Pharmaceutical Ownership Allocation
The majority of Collegium Pharmaceutical outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Collegium Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Collegium Pharmaceutical. Please pay attention to any change in the institutional holdings of Collegium Pharmaceutical as this could imply that something significant has changed or is about to change at the company.Collegium Pharmaceutical Profitability Analysis
The company reported the previous year's revenue of 566.77 M. Net Income was 48.16 M with profit before overhead, payroll, taxes, and interest of 345.74 M.About Collegium Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Collegium Pharmaceutical. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Collegium Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Collegium Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Collegium Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Collegium Pharmaceutical. We calculate exposure to Collegium Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Collegium Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 326.2 M | 342.5 M | |
| Pretax Profit Margin | 0.13 | 0.14 | |
| Operating Profit Margin | 0.29 | 0.31 | |
| Net Profit Margin | 0.08 | 0.09 | |
| Gross Profit Margin | 0.58 | 0.65 |
Collegium Pharmaceutical Growth Indicators
Investing in growth stocks can be very risky. If the company such as Collegium Pharmaceutical does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 41.8 M | |
| Quarterly Earnings Growth Y O Y | -0.495 | |
| Forward Price Earnings | 4.845 |
Collegium Pharmaceutical Current Valuation Indicators
Collegium Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Collegium Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Collegium Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Collegium Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Collegium Pharmaceutical's worth.When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.